Quick Answer
ZEVRA THERAPEUTICS, INC. reported Research And Development Expense of $10.16 million for the year ending 2021.
- ZEVRA THERAPEUTICS, INC. showed an increase of +14.9% in Research And Development Expense from 2020 to 2021.
- This data is from ZEVRA THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 31, 2022.
- XBRL data for this metric is available from 2013 to 2021 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $1.04 million | Q2 2014: $1.72 million | Q3 2014: $3.25 million | Q4 2014: $5.91 million | Q1 2015: $2.12 million | Q2 2015: $2.77 million | Q3 2015: $4.33 million | Q4 2015: $4.72 million | Q1 2016: $3.23 million | Q2 2016: $4.99 million | Q3 2016: $4.29 million | Q4 2016: $7.96 million | Q1 2017: $4.11 million | Q2 2017: $4.65 million | Q3 2017: $6.29 million | Q4 2017: $5.54 million | Q1 2018: $11.64 million | Q2 2018: $10.49 million | Q3 2018: $13.33 million | Q1 2019: $8.53 million | Q2 2019: $4.80 million | Q3 2019: $3.62 million | Q1 2020: $2.13 million | Q2 2020: $1.95 million | Q3 2020: $1.71 million | Q1 2021: $2.27 million | Q2 2021: $2.85 million | Q3 2021: $2.24 million | Q1 2022: $3.08 million.
- Over the full 9 years of available data (2013 to 2021), ZEVRA THERAPEUTICS, INC.'s Research And Development Expense has grown by 201.8%.
- Historical annual values: Fiscal year 2021: $10.16 million | Fiscal year 2020: $8.84 million | Fiscal year 2019: $19.42 million | Fiscal year 2018: $41.76 million | Fiscal year 2017: $20.59 million | Fiscal year 2016: $20.47 million | Fiscal year 2015: $13.93 million | Fiscal year 2014: $11.92 million | Fiscal year 2013: $3.37 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: